Novartis Option Fund joins consortium investing $10m in Anchor Therapeutics' series B round.

Anchor Therapeutics, a US-based biotechnology company, has raised $10m in its series B round from a venture consortium including Switzerland-based drugs company Novartis.

Novartis, through its Option fund which also has a licensing agreement worth more than $200m with Anchor, was joined by venture capital firms TVM Capital and HealthCare Ventures in the series B round that might be opened up to other investors.

The three firms had provided $19m to Anchor, which was then known as Ascent Therapeutics,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?